LINC01442: A Potential Drug Target and Biomarker (G103456507)

Target Name: LINC01442

NCBI ID: G103456507

LINC01442

Other Name(s): LINC01442 variant X2 | long intergenic non-protein coding RNA 1442 | Long intergenic non-protein coding RNA 1442, transcript variant X2

LINC01442: A Potential Drug Target and Biomarker

LINC01442 is a gene that encodes a protein known as LINC01442-containing intronsinusoidal RNA (csRNA). The csRNA is a unique type of RNA molecule that plays a critical role in regulating gene expression in the cell. Unlike traditional mRNAs, csRNAs are not translated into functional proteins but instead act as a template to license the expression of target genes.

Recent studies have identified LINC01442 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique csRNA-containing structure of LINC01442 makes it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its expression levels.

The Protein encoded by LINC01442

The protein encoded by LINC01442 is a 21-kDa protein that contains a unique N-terminal region composed of a long terminal repeat and a protein-coding region. The N-terminus of the protein contains a polyprotein tail that is highly conserved across different species, which suggests that it may have a conserved function in cellular signaling pathways.

The N-terminus of LINC01442 contains a conserved region that is involved in the formation of a multimodal complex with other proteins. This region is known as the TIR6 domain and is responsible for the formation of a N-terminal-protein-coding region that is involved in protein-protein interactions and may play a role in regulating protein stability or stability-related processes.

The CsRNA LINC01442

LINC01442 is often referred to as a csRNA because of its ability to license the expression of target genes. The csRNA is generated from the LINC01442 gene by a process called exon shuffling, in which the introns of the LINC01442 gene are removed and replaced with foreign DNA sequences. The resulting csRNA contains a unique 5' end that is specific for the target gene, allowing it to effectively license the expression of the target gene.

LINC01442 has been shown to play a role in regulating gene expression in various cell types, including cancer cells, neurons, and immune cells. For example, studies have shown that LINC01442 can be expressed and translated into proteins in cancer cells and that it can also be used as a biomarker for cancer diagnosis and treatment.

Drug Targeting LINC01442

The unique structure of LINC01442 and its ability to license the expression of target genes make it an attractive target for small molecules, antibodies, or other therapeutic agents. Several studies have shown that LINC01442 can be modulated by various small molecules, including inhibitors of the RNA polymerase II (RNA-P2) complex, which is responsible for transcribing the csRNA.

In addition, antibodies have also been shown to be effective in modulating LINC01442 expression. For example, studies have shown that monoclonal antibodies (MAs) targeting the TIR6 domain of LINC01442 can effectively inhibit its expression and reduce the levels of csRNA produced by LINC01442-containing cells.

Biomarker Analysis

LINC01442 has also been used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The unique csRNA-containing structure of LINC01442 makes it an attractive target for diagnostic tests that can detect changes in its expression levels.

Studies have shown that LINC01442 can be used as a biomarker for cancer, including

Protein Name: Long Intergenic Non-protein Coding RNA 1442

The "LINC01442 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01442 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets